A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Coronaviruses have caused several epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Some prophylactic vaccines and therapeutic antibodies have already showed striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as...

詳細記述

保存先:
書誌詳細
出版年:bioRxiv
主要な著者: Liu, Hejun, Yuan, Meng, Huang, Deli, Bangaru, Sandhya, Lee, Chang-Chun D., Peng, Linghang, Zhu, Xueyong, Nemazee, David, van Gils, Marit J., Sanders, Rogier W., Kornau, Hans-Christian, Reincke, S. Momsen, Prüss, Harald, Kreye, Jakob, Wu, Nicholas C., Ward, Andrew B., Wilson, Ian A.
フォーマット: Artigo
言語:Inglês
出版事項: Cold Spring Harbor Laboratory 2021
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7885913/
https://ncbi.nlm.nih.gov/pubmed/33594361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.11.430866
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料